Table 2.
Associations Between Baseline Levels of Soluble and Cellular Markers and Bone Loss at 96 Weeks
| Marker | Spine BMD |
Hip BMD |
||
|---|---|---|---|---|
| Estimate (95% CI) | P Value | Estimate (95% CI) | P Value | |
| hsCRPa | −0.02 (−.31 to .27) | .88 | −0.45 (−.70 to −.20) | <.001 |
| IL-6a | −0.16 (−.65 to .33) | .53 | −0.67 (−1.11 to −.24) | .002 |
| sIL-2Ra | −0.05 (−.86 to .75) | .89 | −0.66 (−1.38 to .07) | .07 |
| sCD14a | −0.57 (−2.18 to 1.04) | .49 | −1.67 (−3.10 to −.24) | .02 |
| sCD163a | 0.18 (−.54 to .90) | .62 | −0.04 (−.69 to .60) | .90 |
| Osteoprotegerina | −0.03 (−1.01 to .96) | .96 | −0.25 (−1.14 to .63) | .57 |
| RANKLa | 0.15 (−.12 to .41) | .28 | 0.20 (−.03 to .44) | .09 |
| CD4+CD28−CD57+b | −0.02 (−.32 to .28) | .91 | 0.09 (−.18 to .36) | .51 |
| CD4+CD28−CD57+PD1+a | −4.94 (−8.65 to −1.23) | .009 | −1.86 (−5.18 to 1.46) | .27 |
| CD8+CD28−CD57+b | 0.05 (−.19 to .29) | .68 | 0.06 (−.15 to .27) | .58 |
| CD8+CD28−CD57+PD1+a | 0.04 (−4.17 to 4.24) | .99 | 0.34 (−3.39 to 4.07) | .86 |
| CD4+CD38+HLA-DR+b | −0.26 (−.45 to −.06) | .01 | 0.02 (−.16 to .20) | .81 |
| CD8+CD38+HLA-DR+b | −0.01 (−.20 to .18) | .92 | 0.00 (−.17 to .18) | .98 |
All models are adjusted for age, sex, race, body mass index, baseline CD4+ T-cell count, and human immunodeficiency virus type 1 RNA load.
Abbreviations: BMD, bone mineral density; CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; RANKL, receptor activator of nuclear factor-κ B ligand; sCD14, soluble CD14; sCD163, soluble CD163; sIL-2R, soluble interleukin 2 receptor.
a Estimates represent the percentage change per doubling of the soluble biomarker level.
b Estimates represent the percentage change per 5% change in the cellular marker level.
c Estimates represent the percentage change per 1% change in the cellular marker level.